Brainsway Ltd
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, sc… Read more
Brainsway Ltd (BWAY) - Net Assets
Latest net assets as of September 2025: $70.06 Million USD
Based on the latest financial reports, Brainsway Ltd (BWAY) has net assets worth $70.06 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($113.06 Million) and total liabilities ($43.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $70.06 Million |
| % of Total Assets | 61.97% |
| Annual Growth Rate | 1.62% |
| 5-Year Change | 217.37% |
| 10-Year Change | 383.23% |
| Growth Volatility | 89.73 |
Brainsway Ltd - Net Assets Trend (2000–2024)
This chart illustrates how Brainsway Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Brainsway Ltd (2000–2024)
The table below shows the annual net assets of Brainsway Ltd from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $62.31 Million | +49.86% |
| 2023-12-31 | $41.58 Million | -8.41% |
| 2022-12-31 | $45.40 Million | -20.81% |
| 2021-12-31 | $57.33 Million | +191.97% |
| 2020-12-31 | $19.63 Million | -18.93% |
| 2019-12-31 | $24.22 Million | +248.39% |
| 2018-12-31 | $6.95 Million | -45.35% |
| 2017-12-31 | $12.72 Million | +23.66% |
| 2016-12-31 | $10.29 Million | -20.22% |
| 2015-12-31 | $12.89 Million | -17.22% |
| 2014-12-31 | $15.58 Million | +6.32% |
| 2013-12-31 | $14.65 Million | +62.65% |
| 2012-12-31 | $9.01 Million | -78.75% |
| 2000-12-31 | $42.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Brainsway Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9838100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $413.00K | 0.66% |
| Other Comprehensive Income | $-2.19 Million | -3.51% |
| Other Components | $162.47 Million | 260.73% |
| Total Equity | $62.31 Million | 100.00% |
Brainsway Ltd Competitors by Market Cap
The table below lists competitors of Brainsway Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nanjing Central Emporium Group Stocks Co Ltd
SHG:600280
|
$225.47 Million |
|
National CineMedia Inc
NASDAQ:NCMI
|
$225.48 Million |
|
Jiusheng Electric Co. LTD
SHE:301082
|
$225.53 Million |
|
Shandong Longertek Technology Co Ltd
SHE:300594
|
$225.55 Million |
|
Dogus Gayrimenkul Yatirim Ortakligi AS
IS:DGGYO
|
$225.44 Million |
|
Hengsheng Energy Co Ltd
SHG:605580
|
$225.38 Million |
|
Voneseals Technology (Shanghai) Inc. A
SHE:301161
|
$225.37 Million |
|
Assystem SA
F:BZ1
|
$225.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Brainsway Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 41,581,000 to 62,313,000, a change of 20,732,000 (49.9%).
- Net income of 2,921,000 contributed positively to equity growth.
- New share issuances of 16,353,000 increased equity.
- Other factors increased equity by 1,458,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.92 Million | +4.69% |
| Share Issuances | $16.35 Million | +26.24% |
| Other Changes | $1.46 Million | +2.34% |
| Total Change | $- | 49.86% |
Book Value vs Market Value Analysis
This analysis compares Brainsway Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.66x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 34.14x to 7.66x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.40 | $13.73 | x |
| 2013-12-31 | $0.61 | $13.73 | x |
| 2014-12-31 | $1.09 | $13.73 | x |
| 2015-12-31 | $0.89 | $13.73 | x |
| 2016-12-31 | $0.71 | $13.73 | x |
| 2017-12-31 | $1.72 | $13.73 | x |
| 2018-12-31 | $0.42 | $13.73 | x |
| 2019-12-31 | $2.36 | $13.73 | x |
| 2020-12-31 | $0.87 | $13.73 | x |
| 2021-12-31 | $1.84 | $13.73 | x |
| 2022-12-31 | $1.38 | $13.73 | x |
| 2023-12-31 | $1.25 | $13.73 | x |
| 2024-12-31 | $1.79 | $13.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Brainsway Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.12%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.51x
- Recent ROE (4.69%) is above the historical average (-44.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -120.88% | -1624.27% | 0.03x | 2.18x | $-6.41 Million |
| 2013 | -91.00% | -598.99% | 0.07x | 2.28x | $-7.90 Million |
| 2014 | -42.02% | -193.64% | 0.13x | 1.65x | $-8.10 Million |
| 2015 | -31.69% | -60.10% | 0.31x | 1.72x | $-5.38 Million |
| 2016 | -23.30% | -20.80% | 0.58x | 1.94x | $-3.43 Million |
| 2017 | -55.45% | -63.29% | 0.41x | 2.12x | $-8.33 Million |
| 2018 | -93.20% | -39.51% | 0.69x | 3.39x | $-7.17 Million |
| 2019 | -42.64% | -44.71% | 0.60x | 1.60x | $-12.75 Million |
| 2020 | -27.43% | -24.41% | 0.65x | 1.73x | $-7.35 Million |
| 2021 | -11.27% | -21.79% | 0.39x | 1.32x | $-12.19 Million |
| 2022 | -29.41% | -49.12% | 0.42x | 1.42x | $-17.89 Million |
| 2023 | -10.09% | -13.20% | 0.50x | 1.51x | $-8.36 Million |
| 2024 | 4.69% | 7.12% | 0.43x | 1.51x | $-3.31 Million |
Industry Comparison
This section compares Brainsway Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Brainsway Ltd (BWAY) | $70.06 Million | -120.88% | 0.61x | $225.45 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |